The Drug That Was Supposed to Kill Diabetes Just Got Approved for Something Nobody Expected

GLP-1 drugs like Ozempic won FDA approvals for addiction, kidney disease, and heart failure in 2026. Here is the full science behind what these drugs are actually doing to the human body.

The GLP-1 receptor agonist family — Ozempic, Wegovy, Mounjaro, and their successors — was created to lower blood sugar in type 2 diabetes. Within three years of their mass adoption, they have accumulated clinical evidence for applications that their original developers did not specifically design them for: cardiovascular disease prevention, chronic kidney disease management, sleep apnoea resolution, and most recently, the reduction of addictive behaviour across substance categories that include alcohol, opioids, and nicotine.

The mechanism behind this breadth is increasingly understood. GLP-1 receptors are not confined to the pancreas and gut where the drugs' diabetes effects originate. They are expressed throughout the brain — including in the mesolimbic dopamine system, the neural architecture that underlies reward, motivation, and addiction. When GLP-1 drugs activate receptors in this system, they blunt the dopamine response to substances of abuse in ways that reduce craving without producing their own addictive potential.

The 2026 FDA expansion of Tirzepatide's approved indications — adding chronic kidney disease and sleep apnoea to its existing diabetes and obesity indications — represents the regulatory recognition of what trials have consistently shown: these drugs have effects that extend far beyond their original indication. The kidney protection mechanism involves reduced inflammation and reduced intraglomerular pressure — the structural damage that progresses chronic kidney disease. The sleep apnoea mechanism involves weight loss that reduces airway obstruction, but also, in some patients, a direct effect on upper airway muscle tone whose mechanism is still being investigated.

For the 750 million people globally living with obesity — the primary driver of demand for GLP-1 drugs — the expanding indication list means that starting the drug for weight management increasingly also provides simultaneous cardiovascular, renal, and potentially addictive behaviour benefits that aren't always communicated at prescription.

The access question remains the defining constraint: GLP-1 drugs cost $900-1,400 per month in the United States without insurance coverage. At these prices, their extraordinary clinical benefits are available primarily to people wealthy enough to pay or insured enough to receive coverage — a distribution that reproduces existing health inequity in a new drug category.